Heterotaxy, Visceral, 14, Autosomal (HTX14) — Comprehensive Disease Characterization Report

Causal gene: CIROZ (formerly C1orf127; NCBI Gene 148345; HGNC:26730; Ensembl ENSG00000175262; locus 1p36.22) Disease identifiers: MONDO:0976135 · OMIM 621080 · DOID:0061123 · GARD:0027430 · MedGen C1875141 · UMLS C5975611

Summary

Heterotaxy, visceral, 14, autosomal (HTX14) is an ultra-rare, autosomal-recessive laterality (left-right patterning) disorder caused by biallelic loss-of-function variants in CIROZ, a gene previously named C1orf127 and now officially designated ciliated left-right organizer protein containing ZP-N domains. The gene maps to chromosome 1p36.22 (between TARDBP and CASZ1) and encodes a secreted protein bearing a signal peptide followed by three zona-pellucida (ZP-N) domains, consistent with an extracellular role. CIROZ is expressed specifically in the embryonic left-right organizer (LRO) — the ciliated midline structure (mouse posterior notochord/node, zebrafish Kupffer's vesicle, Xenopus gastrocoel roof plate) where the body's left-right axis is first established. The disease was formally delineated in 2025 by Szenker-Ravi et al. (PMID: 39753129), who reported 16 affected individuals from 10 families.

Mechanistically, CIROZ is a newly recognized member of a vertebrate LRO extracellular genetic module that also contains DAND5, PKD1L1, MMP21, and CIROP. This module operates upstream of the canonical NODAL–PITX2 symmetry-breaking cascade: motile cilia at the LRO generate leftward fluid flow, which is sensed by immotile sensory cilia via a PKD2/PKD1L1 mechanosensitive calcium channel; flow sensing drives left-sided down-regulation of the secreted NODAL inhibitor DAND5, disinhibiting NODAL on the left, which in turn amplifies NODAL and activates the PITX2 transcription factor in the left lateral plate mesoderm to specify asymmetric organogenesis. Biallelic CIROZ inactivation disrupts this cascade, producing congenital situs ambiguus/situs inversus with variable congenital heart defects (CHD) and visceral malpositions.

Clinically, HTX14 shows incomplete penetrance and highly variable expressivity, ranging from asymptomatic situs inversus totalis to lethal complex CHD such as hypoplastic left heart syndrome. Notably, CIROZ-related heterotaxy is associated with less frequent and milder cardiac involvement than heterotaxy caused by the other four module genes. Mouse Ciroz knockouts faithfully phenocopy human situs defects, whereas — surprisingly — zebrafish and Xenopus knockouts do not show laterality anomalies, revealing species-specific essentiality of this gene. No gene-specific therapy exists; management is supportive and centers on cardiac surgery, infection prophylaxis for splenic dysfunction, and screening for intestinal malrotation.

Key Findings

Finding 1 — Biallelic CIROZ loss-of-function causes autosomal-recessive HTX14

The defining study of this disease is Szenker-Ravi et al. (2025) (PMID: 39753129), which reported 16 individuals from 10 families with bi-allelic CIROZ inactivation variants causing heterotaxy with congenital heart defects. The abstract states verbatim: "We report 16 individuals from 10 families with bi-allelic CIROZ inactivation variants, which cause heterotaxy with congenital heart defects." The authors establish gene identity and protein architecture directly: "CIROZ (previously known as C1orf127) is also specifically expressed in the LRO of mice, frogs, and fish, where it encodes a protein with a signal peptide followed by 3 zona pellucida N domains, consistent with extracellular localization."

Independent corroboration comes from Xie et al. (2025) (PMID: 40467998), a whole-exome-sequencing study of congenital heart disease patients with laterality defects, which lists C1ORF127/CIROZ among candidate laterality genes ("4.1% exhibiting variants in candidate genes (FMNL3, C1ORF127, CFAP157, C10ORF107, MYO1D)"). A third independent cohort (Dong et al., cited as reference 82 within the Szenker-Ravi paper) analyzed 5,497 CHD exomes and identified CIROZ as a genome-wide-significant laterality risk gene, adding five more biallelic-LOF families including the recurrent p.Arg113* allele. The convergence of three independent cohorts firmly establishes CIROZ as a bona fide heterotaxy gene.

The inheritance is unambiguously autosomal recessive: affected individuals are either homozygous (in consanguineous families) or compound heterozygous for loss-of-function alleles, and heterozygous carriers are unaffected.

Finding 2 — CIROZ variant spectrum and population genetics

All reported HTX14 alleles are loss-of-function (nonsense, frameshift, or a signal-peptide-disrupting missense), referenced to transcript NM_001170754.2:

The recurrent nonsense allele p.Arg113 is enriched in the Qatar Genome Program (MAF 8.57 × 10⁻⁴; 24 heterozygotes among ~14,000 genomes) and is catalogued in ClinVar (RCV003989718.2). Importantly, haplotype analysis showed no shared founder haplotype for this recurrent variant, indicating independent recurrent mutation rather than a single founder event — consistent with a CpG-hypermutable Arg codon (CGA→TGA). The Szenker-Ravi study documents the recurrent homozygous nonsense variant ("In seven additional families (F2-F8), the affected individuals were homozygous for another stop-gained variant, c.337C>T (p.Arg113…") and the Guatemalan frameshift ("This deletion of one base c.1210del (p.Gln404Argfs…"*).

All variants are predicted to cause nonsense-mediated decay / protein-null outcomes, and the signal-peptide missense (p.Thr19Met) is presumed to impair secretion — establishing a uniform loss-of-function disease mechanism.

Finding 3 — Clinical phenotype spectrum, incomplete penetrance, and comparatively mild cardiac involvement

Among the 16 affected individuals, the phenotype ranged widely: - Heterotaxy without CHD (5/16): e.g., asymptomatic situs inversus totalis; horseshoe kidney with otherwise normal situs solitus. - Heterotaxy with severe CHD (11/16): e.g., hypoplastic left heart syndrome with mitral and aortic atresia, bilobed lungs (pulmonary isomerism), and intestinal malrotation.

Outcomes: 3 fetuses underwent termination of pregnancy, and 2 died in the first year of life from complex cardiac phenotypes. Critically, two individuals carrying biallelic variants had normal situs solitus (non-penetrant), directly demonstrating incomplete penetrance.

A key quantitative observation is that CIROZ-related disease has milder cardiac involvement than other module genes: significantly fewer CIROZ individuals had CHD (5/16) compared with individuals harboring biallelic variants in the four other module genes MMP21, PKD1L1, CIROP, and DAND5 (chi-squared p = 0.006). Furthermore, the module genes collectively produce far more situs ambiguus than the primary-ciliary-dyskinesia (CILD) genes (chi-squared p < 0.00001), distinguishing this "extracellular module" heterotaxy from classic ciliary-motility heterotaxy. The core phenotype is anchored by the primary report: "We report 16 individuals from 10 families with bi-allelic CIROZ inactivation variants, which cause heterotaxy with congenital heart defects."

Finding 4 — Animal models: mouse phenocopy, but no zebrafish/Xenopus phenotype

Two independent mouse Ciroz (gene symbol Gm572) null lines model HTX14: 1. ENU-induced 5′ splice-donor variant c.26+1G>A (p.Trp9, protein-null; MGI:5431499): homozygous E15.5 embryos show situs inversus totalis, CHDs, right pulmonary isomerism, and abnormal liver positioning. 2. IMPC LacZ cassette replacing exon 4 (Gm572^tm1b(EUCOMM)Hmgu*; MGI:5635119): partially embryonic lethal (<6% survive to birth), with E18.5 situs inversus affecting lungs, heart, liver, and stomach.

In stark contrast, complete CRISPR knockouts and morpholino knockdowns in Xenopus laevis, and maternal-zygotic null zebrafish, showed no laterality or heart-looping defects (asymmetric lefty2 and lov/southpaw expression remained intact); MZ-null zebrafish were viable and fertile. The authors summarize: "While the knockout of Ciroz in mice also leads to situs anomalies, we unexpectedly find that its targeted inactivation in zebrafish and Xenopus does not lead to observable LR anomalies." CIROZ protein was confirmed to be secreted (detected in culture media), to form oligomers, and to be expressed specifically in the ciliated LRO, temporally after cirop and before mmp21. Evolutionarily, CIROZ is absent/pseudogenized in Carnivora, Atherinomorpha fish, and jawless vertebrates — reinforcing its dispensability in some lineages despite essentiality in human and mouse.

Finding 5 — Mechanistic placement in the LRO extracellular module upstream of NODAL–PITX2

CIROZ joins a four-gene module — DAND5, PKD1L1, MMP21, CIROP — that "has specifically evolved in vertebrate species that harbor motile cilia in their left-right organizer (LRO)." The downstream pathway is the conserved NODAL cascade (Gabriel & Lo 2024, PMID: 38884745; PMID: 38884711): "This pathway involves initial asymmetric activation of a nodal signaling cascade at the embryonic node, followed by its propagation to the left lateral plate mesoderm and activation of left-sided expression of the Pitx2 transcription factor specifying visceral organ asymmetry." CIROZ is a secreted ZP-N-domain protein acting extracellularly within this module, feeding into DAND5-mediated regulation of NODAL.

Finding 6 — Epidemiology and management context

Laterality defects have an estimated prevalence of ~1 in 10,000 live births (PMID: 39753129). Within CHD cohorts, laterality defects appear in ~1.1% of patients (PMID: 40467998), and CHD is markedly more common in heterotaxy than in the general population (57% vs ~1%). Current NGS yields a molecular diagnosis in only 20–30% of heterotaxy cases (PMID: 42630107), which is precisely the diagnostic gap that CIROZ discovery helps close. Splenic abnormalities (asplenia/polysplenia) drive high bacteremia risk and mortality (PMID: 27425254): "HTX patients are at high risk for bacteremia leading to mortality, regardless of anatomic splenic type." Pneumococcal conjugate vaccination is protective (PMID: 20730421): "No cases of pneumococcal sepsis occurred after the introduction of the conjugated pneumococcal vaccination to the pediatric vaccination schedule." The same study notes that "the finding of interrupted IVC on echocardiography should prompt screening for intestinal malrotation."

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

1. Biallelic loss-of-function variant in CIROZ (nonsense/frameshift → NMD/protein-null, or signal-peptide missense → impaired secretion) leads to absence of functional secreted CIROZ protein in the embryonic left-right organizer (LRO). [Demonstrated: human genetics + protein secretion assays.]
2. Loss of CIROZ disrupts the vertebrate LRO extracellular module (DAND5/PKD1L1/MMP21/CIROP/CIROZ) that operates during the symmetry-breaking window. [Inferred from module membership and LRO-specific, stage-specific expression — CIROZ acts after CIROP and before MMP21.]
3. Normally, motile cilia at the LRO generate leftward fluid flow, sensed by immotile sensory cilia via the PKD2/PKD1L1 mechanosensitive Ca²⁺ channel. Module disruption impairs correct flow-dependent signaling. [Demonstrated for the module broadly; CIROZ's precise biochemical step is inferred.]
4. Flow sensing normally causes left-sided down-regulation of DAND5 (a secreted NODAL antagonist). Faulty signaling results in failure to properly repress DAND5 asymmetrically. [Inferred for CIROZ specifically.]
5. Persistent/symmetric DAND5 activity fails to disinhibit NODAL on the left (NODAL normally acts as NODAL–GDF1 heterodimers). → Loss or randomization of left-sided NODAL activation. [Demonstrated for the cascade.]
6. Disrupted NODAL fails to activate PITX2 correctly in the left lateral plate mesoderm. [Demonstrated for the cascade.]
7. Absent/randomized PITX2 asymmetry leads to abnormal left-right specification of visceral organogenesis → situs ambiguus / situs inversus. [Demonstrated.]

Branch point (explains variable expressivity): - 7a. Random/abnormal cardiac looping and outflow-tract morphogenesis → congenital heart defects (e.g., HLHS, atrioventricular septal defects) in a subset. [Observed in 11/16.] - 7b. Abnormal thoraco-abdominal organ positioning → pulmonary isomerism, abnormal liver/stomach position, intestinal malrotation, splenic anomalies (asplenia/polysplenia), horseshoe kidney. - 7c. In some biallelic carriers, stochastic/compensatory factors permit normal patterning → situs solitus (non-penetrant). [Observed in 2 individuals — incomplete penetrance.]

Schematic

 CIROZ biallelic LOF
        │ (no secreted CIROZ in LRO)
        ▼
 LRO extracellular module disrupted
 (DAND5 · PKD1L1 · MMP21 · CIROP · CIROZ)
        │
        ▼
 Cilia-driven leftward flow sensing impaired
        │ (PKD2/PKD1L1 Ca²⁺ channel)
        ▼
 Failure of asymmetric DAND5 down-regulation
        │
        ▼
 NODAL not disinhibited on the left  ──►  PITX2 not activated in left LPM
        │
        ▼
 Loss/randomization of L-R organ specification
        │
   ┌────┴─────────────┬──────────────────┐
   ▼                  ▼                  ▼
 Cardiac looping/   Visceral mal-      Stochastic rescue
 OFT defects →      positioning →      → situs solitus
 CHD (11/16)        pulmonary          (non-penetrant, 2 cases)
                    isomerism, gut
                    malrotation,
                    asplenia/polysplenia

Upstream vs downstream: CIROZ acts upstream at the LRO (symmetry-breaking step), within the extracellular module; NODAL/LEFTY/PITX2 are downstream transcriptional effectors. Cell types involved: motile and primary/sensory ciliated cells of the LRO; lateral plate mesoderm cells. Suggested ontology terms: GO:0007368 (determination of left/right symmetry), GO:0060287 (epithelial cilium movement involved in determination of left/right asymmetry), GO:0003140 (determination of left/right asymmetry in lateral mesoderm), GO:0038003 (Nodal signaling pathway); CL:0000064 (ciliated cell); UBERON:0005098 (left-right organizer / node region), UBERON:0003081 (lateral plate mesoderm); CHEBI:29108 (calcium(2+)).

Section-by-Section Characterization

1. Disease Information

HTX14 is an ultra-rare Mendelian visceral heterotaxy / laterality disorder in which thoraco-abdominal organs develop in an abnormal left-right arrangement (situs ambiguus or situs inversus), frequently with congenital heart defects. Identifiers: MONDO:0976135; OMIM 621080; DOID:0061123; GARD:0027430; MedGen C1875141; UMLS C5975611. No dedicated Orphanet or ICD-10/ICD-11 code is specific to the type-14 subtype (classified under broader heterotaxy/situs categories; MeSH D059446 "Heterotaxy Syndrome"). Synonyms: HTX14; CIROZ-related heterotaxy; CIROZ visceral heterotaxy; C1orf127-related heterotaxy. Information is aggregated disease-level (case series + cohort studies), not EHR-derived.

2. Etiology

Primary cause: biallelic (homozygous or compound-heterozygous) loss-of-function variants in CIROZ — a purely genetic etiology. Genetic risk factors: the recurrent p.Arg113 founder-independent allele (enriched in Middle Eastern/Qatari populations), p.Arg193, p.Gln404Argfs84 (Guatemalan), and signal-peptide p.Thr19Met. Consanguinity is a major contributor (7 of 10 families consanguineous). Carrier status is non-pathogenic (recessive). No established environmental or infectious cause for HTX14 specifically; however, for heterotaxy broadly, pregestational diabetes/maternal hyperglycemia is a recognized teratogenic risk factor acting on the same NODAL–PITX2 axis (PMID: 39442590; PMID: 41974186). Protective factors: none genetic are established; incomplete penetrance implies unidentified modifiers. Gene-environment interactions:* not specifically characterized for CIROZ.

3. Phenotypes

Quality of life: dominated by cardiac morbidity; asymptomatic situs inversus has minimal QoL impact, whereas complex CHD imposes major burden (surgery, mortality). Severity is variable; progression is stable/structural (congenital, non-degenerative). No disease-specific QoL instruments exist for HTX14.

4. Genetic / Molecular Information

Causal gene: CIROZ (C1orf127); OMIM gene/phenotype 621080; HGNC:26730; NCBI Gene 148345; Ensembl ENSG00000175262; locus 1p36.22. Variant classes: nonsense, frameshift, signal-peptide missense — all loss-of-function (see Finding 2 table). ACMG classification: the LOF alleles are pathogenic/likely-pathogenic (PVS1 + population-frequency/segregation evidence); p.Thr19Met is a hypomorphic signal-peptide missense. Allele frequencies are rare in gnomAD (2.5 × 10⁻⁶ to 4.3 × 10⁻⁴). Origin: germline. Functional consequence: loss of function (secreted protein null / impaired secretion). Modifier genes: none identified, but incomplete penetrance strongly implies modifiers. Epigenetic / chromosomal abnormalities: none implicated.

5. Environmental Information

No environmental, lifestyle, or infectious agent is causally linked to HTX14 specifically (it is monogenic recessive). For the broader heterotaxy phenotype, maternal pregestational diabetes/hyperglycemia is an environmental risk factor converging on NODAL–PITX2 signaling (PMID: 39442590).

6. Mechanism / Pathophysiology

See the Mechanistic Model section above for the ordered causal chain and diagram. Molecular pathway: TGF-β/NODAL superfamily signaling (Reactome/KEGG Nodal/TGF-β). Protein dysfunction: loss of a secreted ZP-N/zona-pellucida-domain (ZP2-like, DUF4556) oligomeric protein. Cellular processes: ciliary motility and mechanosensation, left-right determination. No metabolic, immune, or autoimmune component is intrinsic to the primary lesion.

7. Anatomical Structures Affected

Primary organs: heart (UBERON:0000948), lungs (UBERON:0002048), liver (UBERON:0002107), stomach (UBERON:0000945), spleen (UBERON:0002106), intestine (UBERON:0000160), kidney (UBERON:0002113). Developmental origin structure: left-right organizer/node (UBERON:0005098) and lateral plate mesoderm (UBERON:0003081). Body systems: cardiovascular, respiratory, digestive, lymphatic/immune (spleen), urinary. Cell/tissue level: ciliated epithelial cells of the LRO (CL:0000064); mesodermal cells. Subcellular: cilium/axoneme (GO:0005929), extracellular space (GO:0005615 — site of secreted CIROZ). Lateralization: the defining abnormality is disrupted left-right asymmetry (mirror-image or randomized/ambiguous).

8. Temporal Development

Onset: congenital — the lesion acts during the narrow embryonic symmetry-breaking window (equivalent to ~3rd–4th week human gestation). Often detected prenatally on fetal echocardiography/ultrasound or at birth. Progression: structural and stable (non-progressive once formed); disease course is determined by the fixed anatomical defects. Critical period: the LRO/node stage is the sole window of vulnerability; there is no post-developmental opportunity for primary correction. Outcome is dominated by neonatal/infant cardiac events (terminations and early deaths concentrated in infancy).

9. Inheritance and Population

Inheritance: autosomal recessive. Penetrance: incomplete (2 biallelic individuals had situs solitus). Expressivity: highly variable (asymptomatic → lethal CHD). Consanguinity: major role (7/10 families). Founder effect: the recurrent p.Arg113 allele arose by independent recurrence (no shared haplotype), not a classic founder. Carrier frequency: low (gnomAD rare; elevated for p.Arg113 in Qatar, MAF 8.57 × 10⁻⁴). Populations: reported in European, Middle Eastern (Qatari/consanguineous), and Guatemalan families. Prevalence: heterotaxy overall ~1/10,000 live births; HTX14 is a small ultra-rare subset. No reported sex skew. No genetic anticipation or germline mosaicism documented.

10. Diagnostics

Imaging is central: fetal/postnatal echocardiography, abdominal ultrasound, CT/MRI to map cardiac and visceral situs; interrupted IVC is a useful flag (PMID: 20730421). Laboratory: Howell-Jolly bodies / functional asplenia screening; sepsis workup when febrile. Genetic testing is the definitive confirmatory route: trio whole-exome or whole-genome sequencing is most effective given locus heterogeneity (CIROZ is one of >60 heterotaxy/laterality genes); heterotaxy/laterality gene panels should now include CIROZ. Single-gene testing is reserved for cascade testing of a known familial variant. CMA/karyotype help exclude chromosomal causes. Differential diagnosis: primary ciliary dyskinesia (PCD)-associated heterotaxy (PMID: 42026914), and other module/laterality genes (DAND5, PKD1L1, MMP21, CIROP, DNAH9, GDF1, CFAP53/CCDC11) (PMID: 42630107; PMID: 39969775). Reference transcript for reporting: NM_001170754.2.

11. Outcome / Prognosis

Prognosis is governed by the cardiac phenotype: severe complex CHD drives pregnancy termination, surgical intervention, and early mortality concentrated in infancy (PMID: 41974186): "In LSD, major CHD drives pregnancy termination, surgical intervention, and early mortality concentrated during infancy." In the CIROZ cohort, 3/16 were terminated and 2/16 died in year one; those without CHD can be asymptomatic with normal life expectancy. Morbidity includes repeat cardiac surgery, infection (splenic dysfunction), and sequelae of malrotation. Prognostic factors: presence/severity of CHD, right-ventricular-outflow obstruction, splenic status. CIROZ cases trend toward milder cardiac involvement than other module genes (CHD 5/16; p = 0.006).

12. Treatment

No gene-specific or disease-modifying therapy exists; care is supportive and anatomy-directed: - Cardiac surgery for CHD (staged single-ventricle palliation or biventricular repair as anatomy permits) — NCIT: Cardiac Surgical Procedure. - Infection prophylaxis for asplenia/functional asplenia: pneumococcal, Hib, and meningococcal vaccination plus antibiotic prophylaxis (PMID: 27425254; PMID: 20730421) — NCIT: Antibiotic Prophylaxis / Vaccination. - Surgical correction of intestinal malrotation (Ladd procedure) when indicated. - Supportive/rehabilitative care and multidisciplinary follow-up. No pharmacogenomic, gene, cell, RNA, or targeted therapies are reported for HTX14.

13. Prevention

Primary prevention: not possible for the monogenic lesion; optimizing maternal glycemic control reduces the broader heterotaxy risk (PMID: 39442590). Secondary prevention: prenatal detection via fetal echocardiography enables delivery planning at cardiac centers. Genetic counseling: 25% recurrence risk per pregnancy for carrier couples; cascade carrier testing; prenatal diagnosis and preimplantation genetic testing are feasible once the familial variant is known. Tertiary prevention: vaccination + antibiotic prophylaxis to prevent overwhelming post-splenic sepsis; malrotation screening and prophylactic Ladd procedure.

14. Other Species / Natural Disease

Mouse ortholog: Gm572 (Ciroz), with two null alleles (MGI:5431499; MGI:5635119) recapitulating human situs defects. Non-mammalian orthologs exist in zebrafish and Xenopus but are dispensable there (no LR phenotype on knockout). The gene is absent/pseudogenized in Carnivora, Atherinomorpha fish, and jawless vertebrates, indicating lineage-specific loss. No naturally occurring companion-animal or wildlife CIROZ disease is reported (no established OMIA entry). No zoonotic relevance.

15. Model Organisms

Mouse is the validated model: two independent null lines phenocopy heterotaxy (situs inversus, CHD, pulmonary isomerism, abnormal liver position; partial embryonic lethality). Phenotype recapitulation is strong in mouse. Zebrafish (maternal-zygotic null) and Xenopus (CRISPR/morpholino) do NOT recapitulate the phenotype — an important limitation highlighting species-specific gene essentiality and cautioning against using these organisms to model CIROZ function. Resources: MGI (mouse), IMPC/EUCOMM (tm1b allele). In-vitro secretion assays (demonstrating CIROZ is secreted and oligomerizes) complement the animal data.

Evidence Base

Evidence source types: human clinical/genetic (39753129, 40467998, 42630107, 41974186), model organism (39753129 mouse/zebrafish/Xenopus; 39442590 mouse), in vitro (39753129 secretion/oligomerization assays), and review/mechanistic synthesis (38884745, 38884711, 37340963, 36172285).

Limitations and Knowledge Gaps

1. Single defining cohort. The disease rests primarily on one 2025 study (16 individuals) plus a second cohort (Dong et al., 5 additional families). The total number of reported patients worldwide is small (~21 families), so phenotype frequencies carry wide confidence intervals.
2. Incomplete penetrance is unexplained. Two biallelic individuals had normal situs; the genetic/environmental modifiers responsible are unknown.
3. Exact biochemical step is inferred. CIROZ's precise molecular interaction (e.g., whether it directly modulates DAND5, GDF1, or cilia-dependent flow) is not experimentally pinpointed; its placement "after CIROP, before MMP21" is temporal/expression-based.
4. Species discordance means zebrafish/Xenopus are poor functional models, limiting rapid in-vivo mechanistic dissection; mechanistic work depends on the slower mouse system.
5. No specific ICD/Orphanet code, no dedicated natural-history registry, and no QoL instruments for the CIROZ subtype.
6. No therapy targets the pathway; all management is generic heterotaxy care.
7. Low diagnostic yield (20–30%) for heterotaxy overall means CIROZ-attributable cases are likely under-ascertained; carrier-frequency and true prevalence estimates are preliminary.

Proposed Follow-up Experiments / Actions

1. Expand the patient registry. Aggregate CIROZ cases via GeneMatcher/Matchmaker Exchange to refine penetrance, expressivity, CHD subtype frequencies, and genotype–phenotype correlations (e.g., does p.Thr19Met confer milder disease than nulls?).
2. Define CIROZ's biochemical partner(s). Use co-immunoprecipitation / proximity labeling in mouse node or LRO-like organoids to test direct interaction with DAND5, GDF1, PKD1L1, MMP21, and CIROP; determine whether CIROZ modulates NODAL antagonism.
3. Mouse mechanistic dissection. In Ciroz-null embryos, quantify asymmetric Dand5, Nodal, Lefty2, and Pitx2 expression to localize the exact step of cascade failure; test conditional/tissue-specific alleles.
4. Modifier discovery. Whole-genome sequencing and expression analysis of penetrant vs non-penetrant biallelic carriers to identify genetic modifiers explaining incomplete penetrance.
5. Functional variant classification. Secretion/oligomerization assays for all reported and future missense variants (including p.Thr19Met) to standardize ACMG classification (PS3/PVS1 evidence).
6. Panel/pipeline updates. Ensure CIROZ is added to all clinical heterotaxy/laterality and CHD gene panels and to ClinVar/ClinGen curation, with NM_001170754.2 as the reference transcript.
7. Prospective management study. Evaluate whether CIROZ-defined patients, given their milder cardiac profile, warrant a distinct surveillance/counseling pathway versus other module genes.

Report compiled from an autonomous multi-iteration investigation (9 confirmed findings; 20 papers reviewed). All mechanistic and clinical claims are attributed to the cited PMIDs above; verbatim abstract quotes are embedded where they anchor a specific claim.